Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders

Pharmacogenomics Journal

Volumn 4, Issue 4, 2004, Pages 267-273

  Serretti, Alessandro ^a   Malitas, P N ^b   Mandelli, L ^a   Lorenzi, C ^a   Ploia, C ^a   Alevizos, B ^b   Nikolaou, C ^b   Boufidou, F ^b   Christodoulou, G N ^b   Smeraldi, E ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bipolar disorder; Follow up studies; Lithium; Pharmacogenetics

Indexed keywords

CARBAMAZEPINE; GENOMIC DNA; LITHIUM; SEROTONIN TRANSPORTER; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENOTYPE; GREECE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OUTPATIENT DEPARTMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTEIN VARIANT; PSYCHIATRIC DEPARTMENT; SAMPLING; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

AGE OF ONSET; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; FEMALE; GENOTYPE; HUMANS; LITHIUM; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MOOD DISORDERS; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PSYCHOTIC DISORDERS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THYROID DISEASES;

EID: 4344652232     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500252     Document Type: Article

References (88)

1. Goodwin F, Jamison K. Manic-depressive Illness. Oxford University Press: New York 1990.
2. Schou M. Lithium Treatment of Manic Depressive Illness. A Practical Guide. Karger: Basal 1989.
3. Maj M, Arena F, Lovero N, Pirozzi R, Kemali D. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder. Pharmacopsychiatry 1985; 18: 309-313.
4. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord 1989; 17: 237-241.
5. OConnell RA, Mayo JA, Flatow L, Cuthbertson BO, Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123-129.
6. Abou-Saleh MT. Who responds to prophylactic lithium therapy? Br J Psychiatry 1993; 21(Suppl 21): 20-26.
7. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999; 249: 227-230.
8. Serretti A, Lattuada E, Franchini L, Smeraldi E. Melancholic features and response to lithium prophylaxis in mood disorders. Depression Anxiety 2000; 11: 73-79.
9. Mendlewicz J, Fieve RR, Stallone F, Fleiss JL. Genetic history as a predictor of lithium response in manic-depressive illness. Lancet 1972; 1: 599-600.
10. Maj M, Del Vecchio M, Starace F, Pirozzi R, Kemali D. Prediction of affective psychoses response to lithium prophylaxis. The role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatrica Scand 1984; 69: 37-44.
11. Grof P, Alda M, Grof E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord 1994; 32: 85-95.
12. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10: 115-125.
13. Mendlewicz J. Prediction of treatment outcome: family and twin studies in lithium prophylaxis and the question of lithium red blood cell/plasma ratio. In: Cooper TB, Gershon S, Kline NS, Schou M (eds). Litium Controversis and Unresolved Issues. Excerpta Medica: Amsterdam, 1979.
14. Nylander PO, Engstrom C, Nordqvist-Karlsson B, Astrom M. Family history of affective disorders and the significance for prophylactic effect of lithium treatment. Biol Psychiatry 1999; 45: 1079-1081.
15. Morabito A, Gasperini M, Macciardi F, Smeraldi E. Possible relationship between outcome in primary affective disorders treated with lithium and family history. Adv Biochem Psychopharmacol 1982; 32: 157-163.
16. Smeraldi E, Petroccione A, Gasperini M, Macciardi F, Orsini A. The search for genetic homogeneity in affective disorders. J Affect Disord 1984; 7: 99-107.
17. Smeraldi E, Petroccione A, Gasperini M, Macciardi F, Orsini A, Kidd KK. Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J Affect Disord 1984; 6: 139-151.
18. Cavazzoni P, Alda M, Turecki G, Rouleau G, Grof E, Martin R et al. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res 1996; 64: 91-96.
19. Turecki G, Alda M, Grof P, Martin R, Cavazzoni PA, Duffy A et al. No association between chromosome-18 markers and lithium-responsive affective disorders. Psychiatry Res 1996; 63: 17-23.
20. Alda M. Pharmacogenetics of lithium response in bipolar disorder. J Psychiatry Neurosci 1999; 24: 154-158.
21. Dunner DL, Fleiss JL, Fieve RR. Lithium carbonate prophylaxis failure. Br J Psychiatry 1976; 129: 40-44.
22. Misra PC, Burns BH. 'Lithium non-responders' in a lithium clinic. Acta Psychiatrica Scand 1977; 55: 32-40.
23. Strober M, Morrell W, Burroughs J, Lampert C, Danforth H, Freeman R. A family study of bipolar I disorder in adolescence. Early onset of symptoms linked to increased familial loading and lithium resistance. J Affect Disord 1988; 15: 255-268.
24. Engstrom C, Astrom M, Nordqvist-Karlsson B, Adolfsson R, Nylander PO. Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol Psychiatry 1997; 42: 425-433.
25. Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D, Endicott J. Family history and symptoms levels during treatment for bipolar I affective disorder. Biol Psychiatry 2000; 47: 1034-1042.
26. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M et al. Is response to prophylactic lithium a familial trait? Int J Neuropsychopharmacol 2000; 3: 339.
27. Caril M, Afkhami-Dastjerdian S, Reader TA. Effects of a chronic lithium treatment on cortical serotonin uptake sites and 5-HT1A receptors. Neurochem Res 1997; 22: 427-435.
28. Carli M, Reader TA. Regulation of central serotonin transporters by chronic lithium: an autoradiographic study. Synapse 1997; 27: 83-89.
29. El-Mallakh S. Litihum: Actions and Mechanisms. American Psychiatric Press: Washington, DC 1996.
30. Pei Q, Leslie RA, Grahame-Smith DG, Zetterstrom TS. 5-HT efflux from rat hippocampus in vivo produced by 4-aminopyridine is increased by chronic lithium administration. Neuroreport 1995; 6: 716-720.
31. Sharp T, Bramwell SR, Lambert P, Grahame-Smith DG. Effect of short- and long-term administration of lithium on the release of endogenous 5-HT in the hippocampus of the rat in vivo and in vitro. Neuropharmacology 1991; 30: 977-984.
32. Baptista TJ, Hernandez L, Burguera JL, Burguera M, Hoebel BG. Chronic lithium administration enhances serotonin release in the lateral hypothalamus but not in the hippocampus in rats. A microdialysis study. J Neur Trans - Gen Sect 1990; 82: 31-41.
33. Odagaki Y, Koyama T, Matsubara S, Matsubara R, Yamashita I. Effects of chronic lithium treatment on serotonin binding sites in rat brain. J Psychiatric Res 1990; 24: 271-277.
34. Goodwin GM. The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Prog Neuro-Psychopharmacol Biol Psychiatry 1989; 13: 445-451.
35. Artigas F, Sarrias MJ, Martinez E, Gelpi E, Alvarez E, Udina C. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology 1989; 99: 328-332.
36. Hotta I, Yamawaki S, Segawa T. Long-term lithium treatment causes serotonin receptor down-regulation via serotonergic presynapses in rat brain. Neuropsychobiology 1986; 16: 19-26.
37. Treiser SL, Cascio CS, O'Donohue TL, Thoa NB, Jacobowitz DM, Kellar KJ. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science 1981; 213: 1529-1531.
38. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology 1990; 100: 3-12.
39. Cassidy F, Murry E, Carroll BJ. Tryptophan depletion in recently manic patients treated with lithium. Biol Psychiatry 1998; 43: 230-232.
40. Chaouloff F, Gunn SH, Young JB. Serotonin does not mediate the adrenal catecholamine-releasing effect of acute lithium administration in rats. Psychoneuroendocrinology 1992; 17: 135-144.
41. Lacaille JC, Cloutier S, Reader TA. Lithium reduced synaptic transmission and increased neuronal excitability without altering endogenous serotonin, norepinephrine and dopamine in rat hippocampal slices in vitro. Prog Neuro-Psychopharmacol Biol Psychiatry 1992; 16: 397-412.
42. Manji HK, Hsiao JK, Risby ED, Oliver J, Rudorfer MV, Potter WZ. The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry 1991; 48: 505-512.
43. Collier D, Stöber G, Li T, Heils A, Catalano M, Di Bella D et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1996; 1: 453-460.
44. Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P et al. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 1996; 7: 1675-1679.
45. Rees M, Norton N, Jones I, McCandless F, Scourfield J, Holmans P et al. Association studies of bipolar disorder at the human serotonin transporter gene (hSERT; 5HTT). Mol Psychiatry 1997; 2: 398-402.
46. Bellivier F, Laplanche JL, Leboyer M, Feingold J, Bottos C, Allilaire JF et al. Serotonin transporter gene and manic depressive illness: an association study. Biol Psychiatry 1997; 41: 750-752.
47. Mendes de Oliveira JR, Otto PA, Vallada H, Lauriano V, Elkis H, Lafer B et al. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. Am J Med Genet 1998; 81: 225-227.
48. Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES et al. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet 1998; 81: 58-63.
49. Hoehe MR, Wendel B, Grunewald I, Chiaroni P, Levy N, Morris-Rosendahl D et al. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders. Am J Med Genet 1998; 81: 1-3.
50. Esterling LE, Yoshikawa T, Turner G, Badner JA, Bengel D, Gershon ES et al. Serotonin transporter (5-HTT) gene and bipolar affective disorder. Am J Med Genet 1998; 81: 37-40.
51. Gutierrez B, Arranz MJ, Collier DA, Valles V, Guillamat R, Bertranpetit J et al. Serotonin transporter gene and risk for bipolar affective disorder - an association study in a Spanish population. Biol Psychiatry 1998; 43: 843-847.
52. Oruc L, Verheyen GR, Furac I, Jakovljevic M, Ivezic S, Raeymaekers P et al. Association analysis of the 5-HT2C receptor and 5-HT transporter genes in bipolar disorder. Am J Med Genet 1997; 74: 504-506.
53. Ewald H, Flint T, Degn B, Mors O, Kruse TA. A functional variant of the serotonin transporter gene in families with bipolar affective disorder. J Affect Disord 1998; 48: 135-144.
54. Kelsoe J, Remick R, Sadovnick A, Kristbjarnarson H, Flodman P, Spence M et al. Genetic linkage study of bipolar disorder and the serotonin transporter. Am J Med Genet 1996; 67: 215-217.
55. Lenzinger E, Neumeister A, Praschak-Rieder N, Fuchs K, Gerhard E, Willeit M et al. Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene? Psychiatry Res 1999; 85: 241-246.
56. Mundo E, Walker M, Tims H, Macciardi F, Kennedy JL. Lack of linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and bipolar disorder. Am J Med Genet 2000; 96: 379-383.
57. Ospina-Duque J, Duque C, Carvajal-Carmona L, Ortiz-Barrientos D, Soto I, Pineda N et al. An association study of bipolar mood disorder (type I) with the 5-HTTLPR serotonin transporter polymorphism in a human population isolate from Colombia. Neurosci Lett 2000; 292: 199-202.
58. Saleem Q, Ganesh S, Vijaykumar M, Reddy YC, Brahmachari SK, Jain S. Association analysis of 5HT transporter gene in bipolar disorder in the Indian population. Am J Med Genet 2000; 96: 170-172.
59. Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S et al. Association of anxiety-related traits with a polymorphismin the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1530.
60. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenom J 2001; 1: 71-77.
61. Serretti A, Lilli R, Smerladi E. Pharmacogenetics in affective disorders. Eur J Pharmacol 2002; 438: 117-128.
62. Del Zompo M, Ardau R, Palmas MA, Bocchetta A, Reina A, Piccardi MP. Lithium response: association study with two candidate genes. Mol Psychiatry 1999; 4(Suppl 1): s66-s67.
63. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC 1994.
64. Leckman JF, Sholomskas D, Thompson WD, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 1982; 39: 879-883.
65. W.M.A. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
66. Lahiri DK, Nurnberger JIJ. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acid Res 1991; 19: 5444.
67. Erdfelder E, Faul F, Buchner A. GPOWER: A general power analysis program. Behav Res Methods Instrum Comput 1996; 28: 1-11.
68. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ 1988.
69. Rosenthal N, Mazzanti C, Barnett R, Hardin T, Turner E, Lam G et al. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry 1998; 3: 175-177.
70. Flory JD, Manuck SB, Ferrell RE, Dent KM, Peters DG, Muldoon MF. Neuroticism is not associated with the serotonin transporter (5-HTTLPR) polymorphism. Mol Psychiatry 1999; 4: 93-96.
71. Ohara K, Nagai M, Suzuki Y, Ochiai M. Association between anxiety disorders and a functional polymorphism in the serotonin transporter gene. Psychiatry Res 1998; 81: 277-279.
72. Matsushita S, Muramatsu T, Kimura M, Shirakawa O, Mita T, Nakai T et al. Serotonin transporter gene regulatory region polymorphism and panic disorder. Mol Psychiatry 1997; 2: 390-392.
73. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatric Res 1999; 33: 371-377.
74. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998; 3: 534-538.
75. Lovlie R, Berle JO, Stordal E, Steen VM. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet 2001; 11: 41-43.
76. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8: 259-268.
77. Washizuka S, Ikeda A, Kato N, Kato T. Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol 2003; 6: 421-424.
78. Smeraldi E, Benedetti F, Zanardi R. Serotonin transporter promoter genotype and illness recurrence in mood disorders. Eur Neuropsychopharmacol 2002; 12: 73-75.
79. Gasperini M, Scherillo P, Manfredonia MG, Franchini L, Smeraldi E. A study of relapses in subjects with mood disorder on lithium treatment. Eur Neuropsychopharmacol 1993; 3: 103-110.
80. Franchini L, Gasperini M, Smeraldi E. A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. J Affect Disord 1994; 32: 225-231.
81. Hamilton S, Slager S, Kraft J, McGrath P, Knowles J. Genetic Analysis of the Serotonin Transporter in the Treatment of Depression, Pharmacogenetics in Psychiatry Meeting 2003, Green tab: New York.
82. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
83. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323-330.
84. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
85. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119.
86. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-107.
87. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
88. Muller-Oerlinghausen B. Does effective lithium prophylaxis result in a symptom-free state of manic-depressive illness? Some thoughts on the fine-tuning of mood stabilization. Comp Psychiatry 2000; 41: 26-31.